Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals
- PMID: 31439633
- DOI: 10.1212/WNL.0000000000008135
Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals
Comment in
-
Reader response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.Neurology. 2020 Sep 15;95(11):504-505. doi: 10.1212/WNL.0000000000010517. Neurology. 2020. PMID: 32934157 No abstract available.
-
Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.Neurology. 2020 Sep 15;95(11):505. doi: 10.1212/WNL.0000000000010513. Neurology. 2020. PMID: 32934158 No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources